'Inverse association between the total naevus count and melanoma thickness'.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
31
10
2019
accepted:
28
02
2020
pubmed:
15
3
2020
medline:
15
5
2021
entrez:
15
3
2020
Statut:
ppublish
Résumé
Individuals with a high total naevus count (TNC) are at a higher risk to develop melanoma, and screening efforts have been largely focused on this group. However, some studies suggest that melanomas of patients with many nevi are thinner than those of patients with few nevi. Additionally, nodular melanoma has been associated with individuals with a low naevus count. To investigate the association between TNC and melanoma Breslow thickness. A two-centre retrospective study from 1 January 2016 to 1 January 2018. This included three hundred and twenty-six consecutive melanoma patients from two tertiary melanoma centres. The mean age at presentation was 58.3 years (SD = 15.9), and the majority (54.9%, N = 179) were men. Incidence of new in situ and invasive melanomas and correlation with TNC were measured. The mean total naevus count for patients presenting with in situ melanoma was 57.2 (range 4-178), while for patients presenting with invasive disease was 31.5 (P = 0.01). In situ disease was associated with a higher TNC across all ages. For invasive melanoma, a positive association between age and Breslow thickness was observed, while TNC was inversely associated with Breslow thickness. Each additional naevus accounted for a 4% decreased likelihood that the subject had invasive disease. Patients with a higher naevus count had thinner melanomas and more melanomas in situ, independent of age and sex.
Sections du résumé
BACKGROUND
BACKGROUND
Individuals with a high total naevus count (TNC) are at a higher risk to develop melanoma, and screening efforts have been largely focused on this group. However, some studies suggest that melanomas of patients with many nevi are thinner than those of patients with few nevi. Additionally, nodular melanoma has been associated with individuals with a low naevus count.
OBJECTIVE
OBJECTIVE
To investigate the association between TNC and melanoma Breslow thickness.
METHODS
METHODS
A two-centre retrospective study from 1 January 2016 to 1 January 2018. This included three hundred and twenty-six consecutive melanoma patients from two tertiary melanoma centres. The mean age at presentation was 58.3 years (SD = 15.9), and the majority (54.9%, N = 179) were men. Incidence of new in situ and invasive melanomas and correlation with TNC were measured.
RESULTS
RESULTS
The mean total naevus count for patients presenting with in situ melanoma was 57.2 (range 4-178), while for patients presenting with invasive disease was 31.5 (P = 0.01). In situ disease was associated with a higher TNC across all ages. For invasive melanoma, a positive association between age and Breslow thickness was observed, while TNC was inversely associated with Breslow thickness. Each additional naevus accounted for a 4% decreased likelihood that the subject had invasive disease.
CONCLUSION
CONCLUSIONS
Patients with a higher naevus count had thinner melanomas and more melanomas in situ, independent of age and sex.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2303-2307Informations de copyright
© 2020 European Academy of Dermatology and Venereology.
Références
Guy GP Jr, Thomas CC, Thompson T et al. Vital signs: melanoma incidence and mortality trends and projections - United States, 1982-2030. MMWR Morb Mortal Wkly Rep 2015; 64: 591-596.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7-30.
Sms MD, PhD HTM, Bichakjian CK et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol 2019; 80: 208-250.
Long GV, Stroyakovskiy D, Gogas H et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014; 371: 1877-1888.
Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23-34.
Larkin J, Ascierto PA, Dreno B et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014; 371: 1867-1876.
Robert C, Karaszewska B, Schachter J et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372: 30-39.
Rhodes AR, Weinstock MA, Fitzpatrick TB, Mihm MCJ, Sober AJ. Risk factors for cutaneous melanoma. A practical method of recognizing predisposed individuals. JAMA 1987; 258: 3146-3154.
Bauer J, Garbe C. Acquired melanocytic nevi as risk factor for melanoma development. A comprehensive review of epidemiological data. Pigment Cell Res 2003; 16: 297-306.
Chang Y-M, Newton-Bishop JA, Bishop DT et al. A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes. Int J Cancer 2009; 124: 420-428.
Newton-Bishop JA, Chang Y-M, Iles MM et al. Melanocytic nevi, nevus genes, and melanoma risk in a large case-control study in the United Kingdom. Cancer Epidemiol Biomarkers Prev 2010; 19: 2043-2054.
Cadby G, Ward SV, Cole JM, Moses EK, Millward M, Palmer LJ. The association of host and genetic melanoma risk factors with Breslow thickness in the Western Australian Melanoma Health Study. Br J Dermatol 2014; 170: 851-857.
Nufer KL, Raphael AP, Soyer HP. Dermoscopy and Overdiagnosis of Melanoma In Situ. JAMA Dermatol 2018; 154: 398-399.
Liu W, Dowling JP, Murray WK et al. Rate of growth in melanomas. Arch Dermatol 2006; 142: 1551-1558.
Geller AC, Mayer JE, Sober AJ et al. Total nevi, atypical nevi, and melanoma thickness: an analysis of 566 patients at 2 US centers. JAMA Dermatol 2016; 152: 413-418.
Tan SY, Strazzulla LC, Li X, Park JJ, Lee SJ, Kim CC. Association of clinicopathological features of melanoma with total naevus count and a history of dysplastic naevi: a cross-sectional retrospective study within an academic centre. Clin Exp Dermatol 2018; 43: 566-572.
Ribero S, Davies JR, Requena C et al. High nevus counts confer a favorable prognosis in melanoma patients. Int J Cancer 2015; 137: 1691-1698.
Ewb MD, PhD AW, PhD SN et al. Systematic skin cancer screening in Northern Germany. J Am Acad Dermatol 2012; 66: 201-211.
Katalinic A, Waldmann A, Weinstock MA et al. Does skin cancer screening save lives? Cancer 2012; 118: 5395-5402.
Moloney FJ, Guitera P, Coates E et al. Detection of primary melanoma in individuals at extreme high risk. JAMA Dermatol 2014; 150: 819-819.
Li W-Q, Cho E, Weinstock MA, Li S, Stampfer MJ, Qureshi AA. Cutaneous nevi and risk of melanoma death in women and men: A prospective study. J Am Acad Dermatol 80: 1284-1291.
Argenziano G, Giacomel J, Zalaudek I et al. Twenty nevi on the arms. Eur J Cancer Prev 2014; 23: 458-463.
Frangos JE, Duncan LM, Piris A et al. Increased diagnosis of thin superficial spreading melanomas: A 20-year study. J Am Acad Dermatol 2012; 67: 387-394.
Weinstock MA, Lott JP, Wang Q et al. Skin biopsy utilization and melanoma incidence among Medicare beneficiaries. Br J Dermatol 2017; 176: 949-954.
Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ 2005; 331: 481.